Palatin Technologies Inc New (PTN) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY...

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for...

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire CRANBURY...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR...

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15...

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide...